iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Suven Pharma to buy 67.5% stake in Sapala Organic for Rs 229.5 crore

14 Jun 2024 , 12:06 PM

Suven Pharmaceuticals, funded by PE company Advent International, announced on Thursday that it has signed a formal agreement to acquire a controlling stake in Hyderabad-based contract research development organisation (CDMO) Sapala Organic for ₹229.5 Crore in an all-cash transaction.

According to the provisions of the definitive agreements, Suven would initially acquire a 67.5% equity ownership in Sapala, subject to usual working capital and net debt adjustments, with the remaining portion acquired a few months after FY2026-27.

Sapala had sales of more than ₹67 crore and adjusted EBITDA margins of roughly 45% in FY24.

Sapala is a CDMO player that focuses on oligonucleotides. Oligonucleotides are short DNA or RNA molecules used in pharmaceuticals and diagnostics.

The oligonucleotide building blocks market is valued at $750 million and is predicted to develop at a 20% CAGR.

Sapala is one of the few players with a large customer base that includes innovative pharma, CDMOs, and diagnostic firms. It is also a significant partner in its Oligo drug NCE programmes.

“With this acquisition, we now have several distinct technological platforms, including antibody-drug conjugates (ADCs) and oligos, among others. Suven Pharma’s executive chairman, Annaswamy Vaidheesh, stated that the company will continue to spend both organically and inorganically to expand on these successes.

Sapala was founded by P Yella Reddy, who has over 20 years of experience in nucleic acid chemistry and previously worked as Director (R&D) with Aisin Cosmos R&D Co. Ltd (Toyota Group) in Japan and India. Reddy will continue to run the business as CEO and serve as a strategic advisor for the Japanese market on the Suven+Chance platform.

At around 10.00 AM, Suven Pharma was trading 3.29% higher at ₹689.95, against the previous close of ₹667.95 on NSE. The counter touched an intraday high and low of ₹705, and ₹686, respectively.

For feedback and suggestions, write to us at editorial@iifl.com

For opening a demat account click on: https://www.indiainfoline.com/

For doing stock trading & investments, go to: https://ttweb.indiainfoline.com/trade/Login.aspx

For loans, go to: https://www.iifl.com/

 

 

Related Tags

  • Suven Pharma
  • Suven Pharma Investment
  • Suven Pharma news
  • Suven Pharma Updates
  • Suven Pharmaceuticals
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.